A Danish scientist is filing a counterclaim against GE Healthcare in response to libel charges originally brought by the company over critical statements the radiologist made about potential side effects…
A date has been set for the start of what could be the first trial of a lawsuit involving nephrogenic systemic fibrosis (NSF), a severe and sometimes fatal condition caused…
The results of a new study into side effects of gadolinium MRI contrast agents indicates that patients undergoing dialysis are at 77 fold higher risk of contracting nephrogenic systemic fibrosis…
The makers of Optimark, a gadolinium-based MRI contrasting agent, are changing the warning label to indicate that Optimark should not be used by patients with severe kidney problems. The label…
An FDA advisory committee is planning to review a decision by the agency to place the same warning on all gadolinium-based MRI contrast agents about the risk of nephrogenic systemic…
According to U.S. District Judge Dan Polster, Bayer Healthcare has initiated settlement negotiations with a number of plaintiffs who have filed Nephrogenic Systemic Fibrosis lawsuits after receiving the gadolinium-based Magnevist…
The federal judge overseeing the consolidated Gadolinium litigation involving cases filed on behalf of those who have developed Nephrogenic Systemic Fibrosis after receiving an MRI with contrast, has indicated that…
The FDA has approved a new gadolinium-based contrast agent, Vasovist Injection, which is the first imaging agent approved for use during Magnetic Resonance Imaging (MRA) examinations.
Lawyers for the plaintiffs and lawyers for the manufacturers of gadolinium based MRI contract agents, have filed a joint list of 193 NSF lawsuits which are eligible to be among…
Lawyers involved in the federal litigation over gadolinium-based contrast agents, which have been linked to the development of a debilitating condition known as Nephrogenic Systemic Fibrosis, are scheduled to meet…
